Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 237.47
(3.09%)
USD 237.47
(3.09%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.82 Billion USD | 76.23% |
| 2022 | 1.03 Billion USD | 22.88% |
| 2021 | 844.28 Million USD | 71.31% |
| 2020 | 492.85 Million USD | 124.28% |
| 2019 | 219.75 Million USD | 193.36% |
| 2018 | 74.9 Million USD | -16.69% |
| 2017 | 89.91 Million USD | 90.66% |
| 2016 | 47.15 Million USD | 14.75% |
| 2015 | 41.09 Million USD | -18.72% |
| 2014 | 50.56 Million USD | 7.2% |
| 2013 | 47.16 Million USD | -29.31% |
| 2012 | 66.72 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 500.91 Million USD | -24.08% |
| 2024 Q1 | 494.33 Million USD | 12.42% |
| 2024 Q2 | 659.82 Million USD | 33.48% |
| 2023 Q3 | 750.53 Million USD | 135.46% |
| 2023 Q4 | 439.71 Million USD | -41.41% |
| 2023 FY | 1.82 Billion USD | 76.23% |
| 2023 Q1 | 319.29 Million USD | -4.7% |
| 2023 Q2 | 318.75 Million USD | -0.17% |
| 2022 Q3 | 264.3 Million USD | 17.56% |
| 2022 Q2 | 224.81 Million USD | 5.42% |
| 2022 FY | 1.03 Billion USD | 22.88% |
| 2022 Q1 | 213.25 Million USD | -17.51% |
| 2022 Q4 | 335.03 Million USD | 26.76% |
| 2021 Q2 | 220.55 Million USD | 24.21% |
| 2021 Q4 | 258.53 Million USD | 37.79% |
| 2021 FY | 844.28 Million USD | 71.31% |
| 2021 Q1 | 177.56 Million USD | 8.56% |
| 2021 Q3 | 187.63 Million USD | -14.93% |
| 2020 Q4 | 163.56 Million USD | 29.96% |
| 2020 FY | 492.85 Million USD | 124.28% |
| 2020 Q3 | 125.85 Million USD | 21.06% |
| 2020 Q2 | 103.96 Million USD | 4.51% |
| 2020 Q1 | 99.47 Million USD | 38.78% |
| 2019 Q1 | 33.29 Million USD | 58.29% |
| 2019 FY | 219.75 Million USD | 193.36% |
| 2019 Q4 | 71.68 Million USD | 2.31% |
| 2019 Q3 | 70.06 Million USD | 56.69% |
| 2019 Q2 | 44.71 Million USD | 34.3% |
| 2018 Q2 | 29.9 Million USD | 36.57% |
| 2018 Q1 | 21.89 Million USD | -42.26% |
| 2018 FY | 74.9 Million USD | -16.69% |
| 2018 Q4 | 21.03 Million USD | 916.58% |
| 2018 Q3 | 2.06 Million USD | -93.08% |
| 2017 Q4 | 37.92 Million USD | 121.83% |
| 2017 FY | 89.91 Million USD | 90.66% |
| 2017 Q3 | 17.09 Million USD | 7.31% |
| 2017 Q2 | 15.93 Million USD | -15.97% |
| 2017 Q1 | 18.96 Million USD | 8.63% |
| 2016 Q1 | 7.34 Million USD | -2.73% |
| 2016 Q2 | 8.7 Million USD | 18.57% |
| 2016 Q4 | 17.45 Million USD | 27.86% |
| 2016 Q3 | 13.65 Million USD | 56.75% |
| 2016 FY | 47.15 Million USD | 14.75% |
| 2015 Q1 | 18.53 Million USD | -22.82% |
| 2015 FY | 41.09 Million USD | -18.72% |
| 2015 Q4 | 7.55 Million USD | 19.4% |
| 2015 Q3 | 6.32 Million USD | -27.18% |
| 2015 Q2 | 8.68 Million USD | -53.15% |
| 2014 Q4 | 24.01 Million USD | 118.91% |
| 2014 Q3 | 10.97 Million USD | 50.4% |
| 2014 Q2 | 7.29 Million USD | -11.84% |
| 2014 Q1 | 8.27 Million USD | -23.71% |
| 2014 FY | 50.56 Million USD | 7.2% |
| 2013 FY | 47.16 Million USD | -29.31% |
| 2013 Q4 | 10.84 Million USD | 20.64% |
| 2013 Q1 | 18.64 Million USD | 119.45% |
| 2013 Q2 | 8.68 Million USD | -53.4% |
| 2013 Q3 | 8.99 Million USD | 3.5% |
| 2012 FY | 66.72 Million USD | 0.0% |
| 2012 Q4 | 8.49 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 95.734% |
| Dynavax Technologies Corporation | 232.28 Million USD | -687.093% |
| Illumina, Inc. | 4.5 Billion USD | 59.407% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 87.798% |
| Biogen Inc. | 9.83 Billion USD | 81.411% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -153667.199% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 51.739% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -47.047% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -200.943% |
| Waters Corporation | 2.95 Billion USD | 38.159% |
| Perrigo Company plc | 4.65 Billion USD | 60.729% |
| uniQure N.V. | 15.84 Million USD | -11440.062% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -6716.135% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -357.81% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -21226.164% |
| bluebird bio, Inc. | 29.49 Million USD | -6098.23% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -8619.439% |
| Imunon, Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 678.4 Million USD | -169.501% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 3.116% |
| Nektar Therapeutics | 90.12 Million USD | -1928.686% |
| Editas Medicine, Inc. | 78.12 Million USD | -2240.274% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 98.762% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -1339.101% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 24.427% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -937.435% |
| Evolus, Inc. | 202.08 Million USD | -804.714% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -5750.722% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 86.062% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -1471.589% |
| FibroGen, Inc. | 147.75 Million USD | -1137.406% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 73.243% |
| OPKO Health, Inc. | 863.49 Million USD | -111.732% |
| Homology Medicines, Inc. | -6.65 Million USD | 27588.979% |
| Geron Corporation | 237 Thousand USD | -771331.224% |
| Exelixis, Inc. | 1.83 Billion USD | 0.105% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -4940.088% |
| Zoetis Inc. | 8.54 Billion USD | 78.601% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -575.644% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -52136.914% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 81.475% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -132.121% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -279.019% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -120.475% |
| Blueprint Medicines Corporation | 249.38 Million USD | -633.135% |
| Insmed Incorporated | 305.2 Million USD | -499.031% |
| TG Therapeutics, Inc. | 233.66 Million USD | -682.452% |
| Incyte Corporation | 3.69 Billion USD | 50.529% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -74.239% |